GeneNews Limited

GeneNews Limited

October 28, 2011 08:30 ET

GeneNews Announces SentinelGx™ Pharmacogenomic and Companion Diagnostic BloodRNA™ Services

Karl Wassmann Joins Management Team as EVP, US Corporate Development

TORONTO, ONTARIO--(Marketwire - Oct. 28, 2011) - GeneNews Limited (TSX:GEN), a molecular diagnostics company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced the launch of SentinelGx™, a suite of pharmacogenomic and companion diagnostic BloodRNA™ services for drug development and personalized health management applications ("SentinelGx"). The SentinelGx services provide complete whole blood transcriptome analysis for RNA expression profiling of inflammatory pathways, immune system response and cell signaling based on the Company's patented Sentinel Principle® technology. A catalog of over 2,200 TaqMan® BloodRNA™ Profiles is now available including pathway-specific, disease-specific and drug-specific gene signature panels clinically proven to express in whole blood. The disease-specific panels include gene signatures for numerous types of cancer, autoimmune, cardiovascular, infectious and neurological diseases. In connection with the SentinelGx launch, GeneNews also announced the appointment of Karl Wassmann to the newly created position of Executive Vice President, US Corporate Development to manage the SentinelGx services.

SentinelGx features a wide menu of core laboratory services including RNA isolation, RNA quality control, bio-banking, real-time qPCR gene expression validation with TaqMan® and SYBR® Green chemistries and a full range of Affymetrix® gene expression profiling services including 3' IVT, Whole-Transcript and SNP Expression Analysis. Pharmacogenomic services include biomarker discovery, pharmacodynamics markers for optimal dosage, drug response for patient stratification, disease prognosis for enrichment of trials and surrogate markers, prediction of adverse effects and integration of DNA and RNA profiling for targeted therapies. A full range of collaborative companion diagnostics services includes biomarker development, assay design and analytical validation, clinical validation, and data analysis based on the Company's unique Sentinel Pair™ regression analysis and methods.

Mr. Wassmann brings more than three decades of senior financial, business development, operations and general management experience to GeneNews. Most recently, he served as President and Chief Executive Officer of Source MDx, a privately-held U.S. company focused on the development of whole blood and rare cell-based inflammation and oncology biomarkers for laboratory developed tests and companion diagnostics. Over the past six years, he led more than 30 biomarker and companion diagnostic prospective clinical development programs totaling over 7,000 patients in collaboration with leading pharmaceutical companies and major academic medical centers. He is a co-inventor on over 65 molecular diagnostic and companion diagnostic patents and pending patent applications for oncology and autoimmune diseases. A Chartered Financial Analyst, Mr. Wassmann is a graduate of Bowdoin College and holds an M.B.A. from the University of Chicago's Booth School of Business.

"We are pleased to welcome an executive of Karl Wassmann's experience to this key position", said Gailina J. Liew, President and Chief Operating Officer of GeneNews. "The SentinelGx business will increase the scope of our commercial activities and highlight the advantages of using our blood-based Sentinel Principle platform technology for pharmacogenomic and companion diagnostic applications to support and accelerate drug development efforts".

About GeneNews

GeneNews is an emerging molecular diagnostics company focused on the application of functional genomics to enable early diagnosis and personalized health management based on disease-specific biomarkers. The Company has a patented core platform technology, the Sentinel Principle®, which has the power to detect and stage virtually any disease or medical condition from a simple blood sample. GeneNews' lead product, ColonSentry, is the world's first blood test for colorectal cancer. For more information on GeneNews and ColonSentry™, visit or

Forward-Looking Statements

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.

Contact Information